Memantine Grindeks

Memantine, the active ingredient in Memantine Grindeks, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition and function.

GNH USA supplies Memantine Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution. Clients benefit from reliable supply chains, transparent pricing, and responsive technical assistance.

Memantine is employed in the treatment of neurodegenerative conditions, particularly Alzheimer’s disease, where excessive glutamate activity contributes to neuronal injury.

Alzheimer’s disease (moderate to severe): provides modest improvements in cognition, daily living activities, and overall clinical assessment, supporting patients and caregivers. Alzheimer’s disease (mild to moderate) in combination with cholinesterase inhibitors: may enhance overall therapeutic effect when used as adjunct therapy.

Memantine may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue - Nausea

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (anaphylaxis) - Cardiac arrhythmia - Hallucinations or psychosis - Liver function abnormalities - Stevens‑Johnson syndrome

When prescribing memantine, clinicians should consider several safety aspects. - Renal impairment: assess renal function and adjust dose if necessary. - Hepatic impairment: use with caution and monitor liver enzymes. - History of seizures: monitor for increased seizure frequency. - Concomitant use with other NMDA antagonists: avoid additive neurotoxicity. - Psychiatric disorders: observe for worsening agitation or psychosis. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Memantine can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Amantadine: increased neuropsychiatric risk. - Other NMDA antagonists (e.g., ketamine): additive neurotoxicity. - Strong CYP3A4 inducers (e.g., carbamazepine): reduced memantine exposure.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may raise plasma memantine levels. - Alcohol: may enhance central nervous system depression.